06955.HK
Shandong Boan Biotechnology Co., Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 3.43
−2.42%Aug 26, 2026, 12:00 UTC
Boan Biotech announced that its investigational drug BA2201, a long-acting bispecific antibody targeting TL1A and IL-23 for inflammatory bowel disease, has had its new drug clinical trial application accepted for review by the Center for Drug Evaluation of China's National Medical Products Administration.
Source:Aug 16, 2026, 13:46 UTC
Boan Biotech announced that its self-developed CD228-targeting antibody-drug conjugate BA1302 has completed the Phase Ia dose-escalation stage of a Phase I clinical study in China, showing good anti-tumor activity and tolerable safety in patients with advanced solid tumors.
Source:Aug 16, 2026, 13:36 UTC
Boan Biotech issued a profit warning, expecting a net loss of RMB 79 million to 89 million for the six months ended June 2026, compared to a profit of RMB 21 million in the same period last year, due to increased R&D expenses from its accelerated innovation strategy.
Source:Aug 5, 2026, 13:54 UTC
Boan Biotech submitted a marketing authorization application to Brazil's ANVISA for its intravitreal injection solution BA9101, intended to treat wet age-related macular degeneration and diabetic macular edema.
Source: